Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass

被引：31

作者：

Davis, Z ^{[1
]}

Anderson, R ^{[1
]}

Short, D ^{[1
]}

Garber, D ^{[1
]}

Valgiusti, A ^{[1
]}

机构：

[1] Edward Hosp, Naperville, IL USA

来源：

ANNALS OF THORACIC SURGERY | 2003年 / 75卷 / 01期

关键词：

D O I：

10.1016/S0003-4975(02)04299-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

An 81-year-old man with previous syncopal episodes, progressive shortness of breath, pulmonary edema, severe calcific aortic stenosis, and a history of heparin-induced thrombocytopenia required aortic valve replacement. Bivalirudin, a thrombin-specific anticoagulant, was used in place of heparin. The patient received a 50 mg bivalirudin bolus followed by an infusion between 1.5 mg (.) kg(-1) (.) h(-1) and 1.75 mg (.) kg(-1) (.) h(-1). Adequate anticoagulation was readily obtained resulting in an uneventful cardiopulmonary bypass. Activated clotting time (ACT) values steadily declined after discontinuation of the bivalirudin infusion. Bivalirudin is a practical alternative to heparin during cardiac surgical procedures. (C) 2003 by The Society of Thoracic Surgeons.

引用

页码：264 / 265

页数：2

共 5 条

[1] Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin [J].